RE:RE:Expectations and milestones for 2024 Either these strategic advisors are idiots or Howard just does not listen.....
Sirona Biochem Retains Strategic Advisor To Commercialize Glycoproteins
Vancouver, British Columbia – November 3, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB) (the "Company") is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason’s role will be primarily to provide strategic advice and an action plan for the Company’s glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere®, which was sold to BTG for $200 million. Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.
“I look forward to working closely with management on the glycoprotein project over the next few months,” said Dr. Mason Ross. “I can’t think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous.”
“We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener,” said Dr. Howard Verrico, CEO of Sirona Biochem.